JOP20170004B1 - الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته - Google Patents

الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته

Info

Publication number
JOP20170004B1
JOP20170004B1 JOP/2017/0004A JOP20170004A JOP20170004B1 JO P20170004 B1 JOP20170004 B1 JO P20170004B1 JO P20170004 A JOP20170004 A JO P20170004A JO P20170004 B1 JOP20170004 B1 JO P20170004B1
Authority
JO
Jordan
Prior art keywords
n3pglu
amyloid beta
peptide antibody
clinical
antibodies
Prior art date
Application number
JOP/2017/0004A
Other languages
English (en)
Inventor
Lu Jirong
Tang Ying
Bradley Demattos Ronald
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JOP20170004B1 publication Critical patent/JOP20170004B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بأجسام مضادة لـ N3pGlu A? البشري، تركيبات تشتمل على الأجسام المضادة لـ N3pGlu A? تلك، وطرق استخدام الأجسام المضادة لـ N3pGlu A? تلك لعلاج مرض يتميز بترسيب A? يتضمن مرض آلزهايمر الإكلينيكي وقبل الإكلينيكي، متلازمة داون، واعتلال وعائي دماغي نشواني إكلينيكي أو قبل إكلينيكي.
JOP/2017/0004A 2016-01-15 2017-01-03 الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته JOP20170004B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662279268P 2016-01-15 2016-01-15

Publications (1)

Publication Number Publication Date
JOP20170004B1 true JOP20170004B1 (ar) 2022-09-15

Family

ID=57966094

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0004A JOP20170004B1 (ar) 2016-01-15 2017-01-03 الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته

Country Status (16)

Country Link
US (1) US9944696B2 (ar)
EP (1) EP3402817B1 (ar)
JP (1) JP6634158B2 (ar)
KR (1) KR102141969B1 (ar)
CN (2) CN114891100B (ar)
AR (2) AR107290A1 (ar)
AU (1) AU2017207250B2 (ar)
CA (1) CA3007000C (ar)
EA (1) EA037784B1 (ar)
ES (1) ES2968255T3 (ar)
IL (1) IL259748B2 (ar)
JO (1) JOP20170004B1 (ar)
MX (1) MX394462B (ar)
TW (1) TWI634126B (ar)
WO (1) WO2017123517A1 (ar)
ZA (2) ZA201803396B (ar)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018031967A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
EA201990473A1 (ru) 2016-08-12 2019-07-31 Эл.И.Эй.Эф. ХОЛДИНГС ГРУП ЭлЭлСи Полиглутамированные антифолаты и их применение
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI705975B (zh) * 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
EP3749311A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
CN111954529A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化氨甲蝶呤及其用途
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
CN111936145A (zh) 2018-02-14 2020-11-13 L.E.A.F.控股集团公司 γ聚谷氨酸化氨甲蝶呤及其用途
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
MA55491A (fr) * 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
AU2022376940A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
AU2022376930A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
WO2025228315A1 (en) * 2024-04-28 2025-11-06 Jacobio Pharmaceuticals Co., Ltd. Anti-n3pglu amyloid beta antibodies and uses thereof
WO2025237397A1 (zh) * 2024-05-16 2025-11-20 江苏恒瑞医药股份有限公司 抗N3pGlu Aβ抗体及其医药用途
TW202607032A (zh) 2024-06-20 2026-02-16 瑞典商生物極公司 雙特異性結合分子
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
WO2009149487A2 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
CA2730073A1 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
EP3338795A1 (en) * 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
AU2014233615B2 (en) * 2010-08-12 2016-08-11 Eli Lilly And Company Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples

Also Published As

Publication number Publication date
MX2018008557A (es) 2018-09-18
AU2017207250B2 (en) 2019-04-18
IL259748B (en) 2022-11-01
KR102141969B1 (ko) 2020-08-06
AR132544A2 (es) 2025-07-16
TW201739761A (zh) 2017-11-16
JP2019507107A (ja) 2019-03-14
CN114891100A (zh) 2022-08-12
KR20180086268A (ko) 2018-07-30
CA3007000C (en) 2021-07-27
IL259748B2 (en) 2023-03-01
BR112018011308A2 (pt) 2018-11-27
CN108473566B (zh) 2022-06-17
WO2017123517A1 (en) 2017-07-20
US9944696B2 (en) 2018-04-17
ZA201901207B (en) 2022-05-25
TWI634126B (zh) 2018-09-01
EA037784B1 (ru) 2021-05-20
JP6634158B2 (ja) 2020-01-22
ES2968255T3 (es) 2024-05-08
AU2017207250A1 (en) 2018-06-07
EP3402817A1 (en) 2018-11-21
ZA201803396B (en) 2025-08-27
AR107290A1 (es) 2018-04-18
CN108473566A (zh) 2018-08-31
MX394462B (es) 2025-03-11
CA3007000A1 (en) 2017-07-20
EA201891286A1 (ru) 2018-12-28
CN114891100B (zh) 2024-05-03
IL259748A (en) 2018-07-31
US20170204171A1 (en) 2017-07-20
EP3402817B1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
PH12019502361A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
MX394462B (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS.
CU24498B1 (es) Anticuerpos de factor xi
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
HUE053452T2 (hu) Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
EA201691541A1 (ru) Новые анти-baff антитела
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
HUE049083T2 (hu) Humanizált, humán CD19 elleni antitestek és alkalmazási eljárások
MX389684B (es) Anticuerpos anti tigit.
MX392779B (es) Anticuerpos anti-cd27
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
UA123202C2 (uk) Антитіло до тау-білка і його застосування
IL284807A (en) Antibodies specific to human nectin-2
IL284367A (en) Monoclonal antibodies that bind specifically to human trbv9
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
MX391141B (es) Anticuerpos anti-ceramida.
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EP3813878A4 (en) CAR ANTI-BCMA ANTIBODIES, CONJUGATES AND METHODS OF USE